These results suggest that the development of human tau and Aβ neuropathology in mice is insufficient to increase murine ACE2 levels, even when combined with aging and HFD, two risk factors for both AD and COVID-19 infection. The gene discussed is MAPT; the disease is Alzheimer disease.